Ignite Creation Date:
2025-12-24 @ 4:42 PM
Ignite Modification Date:
2026-03-04 @ 2:54 PM
Study NCT ID:
NCT06430866
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2024-03-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Sponsor:
Amgen
Organization:
Study Overview
Official Title:
A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Participants With Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
Status:
RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Eucalyptus
Brief Summary:
The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: